Literature DB >> 17150346

Delays in the diagnostic pathways for primary pulmonary carcinoma in Southern Norway.

Heidi B Rolke1, Per S Bakke, Frode Gallefoss.   

Abstract

BACKGROUND: This study intends to evaluate the delays in the diagnostic pathways for primary lung cancer in Southern Norway, and to compare results with recommendations from the British Thoracic Society (BTS) and the Swedish Lung Cancer Group (SLCG).
DESIGN: A questionnaire-based prospective study of all patients diagnosed with primary lung cancer in Southern Norway from June 14, 2002 to June 13, 2005.
RESULTS: Half of the 479 patients were referred to a specialist in pulmonology within 3 weeks (median) of first seeing their doctor concerning symptoms of malignant pulmonary disease. 71% of patients were seen by pulmonologist within 1 week of received referral, and not 100% as proposed by the BTS. 52% of the patients were diagnosed and informed of their disease within 2 weeks (BTS recommend 100%) of having received the referral letter, and 68% within 3 weeks (SLCG recommend 80%). 62% started treatment within 1 month of first contact with pulmonologist (SLCG 80%).
CONCLUSION: The delays in diagnosing lung cancer in the Agder region were within BTS and Swedish recommendations in 52-71% of cases. Although our results show good standings compared to other studies, the potential improvements for both the referring GP and the specialist investigators are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17150346     DOI: 10.1016/j.rmed.2006.10.021

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Effect of delays on survival in patients with lung cancer.

Authors:  Francisco Javier González-Barcala; José María García-Prim; José Manuel Alvarez-Dobaño; Milagros Moldes-Rodríguez; María Teresa García-Sanz; Antonio Pose-Reino; Luis Valdés-Cuadrado
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

Review 2.  Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers.

Authors:  M Elisabeth Del Giudice; Sheila-Mae Young; Emily T Vella; Marla Ash; Praveen Bansal; Andrew Robinson; Roland Skrastins; Yee Ung; Robert Zeldin; Cheryl Levitt
Journal:  Can Fam Physician       Date:  2014-08       Impact factor: 3.275

Review 3.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

4.  Timeliness of care and prognosis in patients with lung cancer.

Authors:  F J Gonzalez-Barcala; J A Falagan; J M Garcia-Prim; L Valdes; J M Carreira; A Puga; P Martín-Lancharro; M T Garcia-Sanz; D Anton-Sanmartin; J C Canive-Gomez; A Pose-Reino; R Lopez-Lopez
Journal:  Ir J Med Sci       Date:  2013-10-04       Impact factor: 1.568

5.  Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?

Authors:  Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

6.  Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).

Authors:  Usha Menon; Peter Vedsted; David Weller; Alina Zalounina Falborg; Henry Jensen; Samantha Harrison; Irene Reguilon; Andriana Barisic; Rebecca J Bergin; David H Brewster; John Butler; Odd Terje Brustugun; Oliver Bucher; Victoria Cairnduff; Anna Gavin; Eva Grunfeld; Elizabeth Harland; Jatinderpal Kalsi; Anne Kari Knudsen; Mats Lambe; Rebecca-Jane Law; Yulan Lin; Martin Malmberg; Donna Turner; Richard D Neal; Victoria White
Journal:  BMJ Open       Date:  2019-11-27       Impact factor: 2.692

7.  Wait times for diagnosis and treatment of lung cancer: a single-centre experience.

Authors:  C Labbé; M Anderson; S Simard; L Tremblay; F Laberge; R Vaillancourt; Y Lacasse
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

8.  Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Authors:  Hans H Strøm; Roy M Bremnes; Stein H Sundstrøm; Nina Helbekkmo; Ulf Aasebø
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.